QIAGEN reports results for fourth quarter and full-year 2018

QIAGEN’s hereditary disease knowledge extended to NHS Genomic Medicine Service

QIAGEN receives approval for EGFR test in lung cancer as companion diagnostic in Japan

QIAGEN’s QuantiFERON®-TB Gold Plus gains approval in Canada

QIAGEN provides status update on settlement mechanics of convertible notes

QIAGEN launches QIAcube Connect – next-generation automation for sample processing in research labs

QIAGEN acquires N-of-One, expanding its clinical bioinformatics capabilities in molecular oncology decision support

QIAGEN unveils plans for next-generation digital PCR systems

QIAGEN to develop QuantiFERON®-TB Access as a new test for low-resource, high-burden regions in global fight against TB

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase